Parabilis Medicines Q3 2026: Revenue Came In 323% Above Estimates
As seen on the 24/7 Wall St. homepage on November 12, 2026.
A roughly $1.1 billion cash pile now funds Parabilis into 2030, which means no dilution risk while zolucatetide heads toward the PEDESTAL Phase 3 start in the first half of 2027. The quarter also carried first-ever collaboration revenue, more than four times what analysts modeled. Data readouts in FAP, ACP and HCC land early next year.
Continue ReadingShow less
Parabilis Medicines reported its first-ever collaboration revenue in Q3 2026 of $2.11 million. Analysts had modeled just $500,000, meaning the actual result came in 322.8% above expectations, driven by two collaboration agreements including one with a related party.
The loss per share of $0.36 beat the consensus estimate of $0.38 by 5.26%, a smaller but meaningful result given that research and development expenses climbed to $45.6 million as the company accelerated clinical spending on zolucatetide. General and administrative costs also rose, reflecting the costs of operating as a public company, while interest income on the company's expanded cash balance helped partially offset those expenses.
The quarter's most consequential fact for long-term investors is the balance sheet. Parabilis held roughly $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2026, a position the company says is sufficient to fund operations into 2030. That runway effectively removes near-term dilution risk while the company advances its lead program toward the PEDESTAL Phase 3 registrational trial in desmoid tumors, which is slated to begin in the first half of 2027 with topline results anticipated in 2029.
Sponsored
Phase 3 design details have already been aligned with the FDA, covering dose, regimen, and trial structure. CEO Mathai Mammen pointed to updated data presented at ESMO as reinforcing confidence in the depth and consistency of desmoid tumor responses and a favorable safety and tolerability profile, calling the company well positioned to initiate PEDESTAL on schedule.
Beyond desmoid tumors, Parabilis is pursuing zolucatetide across several other Wnt-driven cancers. Translational and additional clinical data in familial adenomatous polyposis (FAP) are expected in the first quarter of 2027, updated data in adamantinomatous craniopharyngioma (ACP) are expected in the first half of 2027, and additional hepatocellular carcinoma (HCC) data are targeted for a medical meeting in the first quarter of 2027. A combination study in RAS G12D mutant MSS colorectal cancer is also underway through a collaboration with Revolution Medicines.
Mentioned: PBLS